Clinical Policy: Implantable Intrathecal Pain Pump

Reference Number: CP.MP.173 [Coding Implications](#Coding_Implications)

Last Review Date: 02/19

[Revision Log](#Revision_Log)

**See** [Important Reminder](#Important_Reminder) **at the end of this policy for important regulatory and legal information.**

## Description

An implantable, intrathecal drug delivery system consists of an implanted pump and catheter that delivers a drug directly into the spinal fluid. The device can be programmed for continuous or variable rates of infusion. Intrathecal drug delivery systems offer an invasive alternative for the long-term management of select patients with intractable pain.

*Refer to CP.PHAR.149 Intrathecal Baclofen (Gablofen, Lioresal) for requests for Baclofen*

*Refer to the CP.MP 107 Durable Medical Equipment (DME) section on Surgical Supplies for criteria for other indications*

## Policy/Criteria

1. It is the policy of health plans affiliated with Centene Corporation® that a *preliminary trial of intrathecal administration of an opioid drug* is **medically necessary** for either of the following indications:
2. Chronic intractable pain of malignant origin when all of the following criteria is met:
   * + 1. Inadequate response to noninvasive methods of pain control such as systemic opioids;
3. Life expectancy > 3 months;
4. No evidence of epidural metastatic lesion(s) or tumor encroachment of the thecal sac by imaging.
5. No local infection at catheter insertion site
6. Chronic intractable pain of nonmalignant origin (e.g. failed back surgery syndrome, complex regional pain syndrome) when all the following criteria is met:
7. Pathology for the pain has been identified;
8. Life expectancy is > 3 months;
9. Failure or inability to tolerate other conservative treatment methods, including but not limited to, systemic pharmacotherapy, physical therapy, behavioral health treatment for pain, and appropriate nonsurgical treatment;
10. Compliance with previous attempts to treat the condition;
11. No current drug and/or alcohol disorder, including but not limited to, opioid use disorder or addiction;
12. A psychological evaluation confirms a mental health condition is not a major contributor to chronic pain symptoms;
13. Active participation in psychotherapeutic interventions (e.g. cognitive behavioral therapy, relaxation training, biofeedback, coping skills training, stress management);
14. Further surgical intervention or other treatment is not indicated or likely to be effective;
15. No local infection at catheter insertion site;
16. Prior to the trial, systemic opioids have been weaned by at least 50%;
17. Opioid induced hyperalgesia has been ruled out as a possible cause of the chronic pain symptoms.
18. It is the policy of health plans affiliated with Centene Corporation that *implantation of a permanent epidural or intrathecal pain pump* to administer an opioid drug, singly or in combination with other non-opioid drugs, is **medically necessary** for either of the following:
19. Chronic intractable pain of malignant origin and the preliminary trial provided ≥ 50% reduction in pain with minimal side effects;
20. Severe chronic pain of non-malignant origin and all of the following criteria:
21. Preliminary trial provided ≥ 50% reduction in pain and increase in function with minimal side effects;
22. There is a plan in place to continue to wean systemic opioids;
23. No known or suspected infection;
24. No active coagulopathy;
25. Body size is sufficient to support the weight and bulk of the device;
26. No other implanted programmable devices where the crosstalk between devices may inadvertently change the prescription;
27. No known allergy or hypersensitivity to the drug being used;
28. No evidence of increased intracranial pressure;
29. No spinal anomalies that may complicate the implantation and fixation of a catheter for drug delivery;
30. Continued active participation in any behavioral health or psychological treatment modalities.

## Background

Chronic pain is often defined as pain that persists longer than 6 months. The American Society of Interventional Pain Physicians (ASIPP) defines chronic pain as “a complex and multifactorial phenomenon with pain that persists 6 months after an injury and/or beyond the usual course of an acute disease or a reasonable time for a comparable injury to heal, that is associated with chronic pathologic processes that cause continuous or intermittent pain for months or years, that may continue in the presence or absence of demonstrable pathology and may not be amenable to routine pain control methods with healing never occurring.”5 Numerous health conditions can cause chronic pain, including, but not limited to, chronic cancer pain, failed back surgery syndrome, complex regional pain syndrome, diabetic neuropathy, and post-herpetic neuralgia.2

Opioid therapy for the treatment of chronic non-cancer pain is controversial, due to insufficient evidence of long-term efficacy and the risk of serious harm, including addiction and abuse, especially in the context of the ongoing opioid epidemic in the United States. For patients with chronic non-cancer pain, opioids should only be used when other potentially effective and safer therapies have not provided sufficient pain relief or experience intolerable side effects, and pain is adversely affecting a patient's function and/or quality of life. The potential benefits of opioid therapy should outweigh potential harms. Opioids should be combined with non-opioid pharmacotherapy and nonpharmacologic therapies as appropriate. 7

Intrathecal therapy offers an invasive alternative for the long-term management of select patients with recalcitrant pain after all other methods have failed, including conservative and surgical treatment. Implantable intrathecal infusion systems, also referred to as intrathecal drug delivery (IDD) systems, provide targeted drug delivery to the central nervous system. They are most commonly used for cancer-related pain. Their use for management of pain of non-malignant origin is controversial and generally reserved for treatment of last resort. A number of medications are used, including opioids (e.g. morphine) or a combination of opioids along with a local anesthetic (e.g., ziconotide, clonidine.)

An implantable intrathecal drug delivery system (pain pump) consist of an implanted catheter and either a constant-flow or programmable pump. The implantation of a pump for intrathecal opioid infusion is preceded by an intrathecal or epidural trial infusion, with or without a catheter, to determine whether the patient exhibits an adequate response, consisting of a predefined improvement in pain (usually ≥ 50%) without intolerable adverse effects. If the trial is successful, the drug infusion system is implanted under general anesthesia. The catheter is introduced into the intrathecal space of the spine (generally at the lumbar level), tunneled subcutaneously, and typically positioned under fluoroscopic guidance so that the tip is located at the corresponding spinal level for processing the patient’s pain. The catheter is connected to an infusion pump placed in a subcutaneous pocket in the abdomen.2 Complications related to intrathecal therapy can be technical, biological, or medication related.5

The literature evaluating intrathecal infusion systems for long-term management of chronic non-cancer pain is limited. Peer reviewed literature to date consists of observational studies, uncontrolled retrospective studies, case studies and systematic reviews using variable methodologies and inclusion criteria. Some studies suggest that intrathecal opioids reduce pain long-term in a small proportion of individuals with chronic, non-cancer pain, however, large randomized controlled trials are lacking.

A health technology assessment of Intrathecal Drug Delivery Systems for Noncancer Pain reported, “Compared with oral opioid analgesia alone or a program of analgesia plus rehabilitation, intrathecal drug delivery systems significantly reduced pain (27% additional improvement) and morphine consumption. Despite these reductions, intrathecal drug delivery systems were not superior in patient-reported well-being or quality of life. There is no evidence of superiority of intrathecal drug delivery systems over oral opioids in global pain improvement and global treatment satisfaction. Comparative evidence of harms was not found.”8

*American Society of Interventional Pain Physicians (ASIPP)*

The evidence is limited for implantable intrathecal drug administration systems in managing patients with failed back surgery syndrome. 9

*American Society of Anesthesiologists/American Society of Regional Anesthesia and Pain Medicine*

Studies with observational findings indicate that intrathecal opioid injections can provide effective pain relief for assessment periods ranging from 1 to 12 months for patients with neuropathic pain (Category B2 evidence).

Consultants, ASA members, and ASRA members are equivocal with regard to whether intrathecal opioid injection or infusion should be used for neuropathic pain. However,

they strongly agree that neuraxial opioid trials should be performed before considering permanent implantation of intrathecal drug delivery systems.6

*North American Spine Society (NASS)*

NASS has developed coverage recommendation on spinal intrathecal drug delivery systems for the treatment of chronic nonmalignant pain. Per NASS, the implantable infusion may benefit a small subgroup of patients with chronic nonmalignant pain and a clear spinal pathology, who have exhausted all other options to treat their symptoms. These patients should have a psychological evaluation to rule out drug and alcohol disorders and other psychological conditions.9

**Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| **CPT® Codes** | **Description** |
| --- | --- |
| 62320 | Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance |
| 62321 | Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (ie, fluoroscopy or CT) |
| 62322 | Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance |
| 62323 | Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (i.e., fluoroscopy or CT) |
| 62326 | Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance |
| 62327 | Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (i.e., fluoroscopy or CT) |
| 62350 | Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without laminectomy |
| 62351 | Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; with laminectomy |
| 62355 | Removal of previously implanted intrathecal or epidural catheter |
| 62360 | Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir. |
| 62361 | Implantation or replacement of device for intrathecal or epidural drug infusion; nonprogrammable pump |
| 62362 | Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming |
| 62365 | Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion |
| 62367 | Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming or refill |
| 62368 | Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming |
| 62369 | Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill |
| 62370 | Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional) |

| **HCPCS Codes** | **Description** |
| --- | --- |
| A4300 | Implantable access catheter, (e.g., venous, arterial, epidural subarachnoid, or peritoneal, etc.) external access |
| A4301 | Implantable access total catheter, port/reservoir (e.g., venous, arterial, epidural, subarachnoid, peritoneal, etc.) |
| E0782 | Infusion pump, implantable, nonprogrammable (includes all components, e.g., pump, catheter, connectors, etc.) |
| E0783 | Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.) |
| E0785 | Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement |
| E0786 | Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) |
| C1772 | Infusion pump, programmable (implantable) |
| C1755 | Catheter, intraspinal |
| J2274 | Injection, morphine sulfate, preservative free for epidural or intrathecal use, 10 mg |
| S0093 | Injection, morphine sulfate, 500 mg (loading dose for infusion pump) |

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

+ Indicates a code requiring an additional character

| **ICD-10 Codes** | **Description** |
| --- | --- |
| G57.70 | Causalgia of unspecified lower limb |
| G57.71 | Causalgia of right lower limb |
| G57.72 | Causalgia of left lower limb |
| G57.73 | Causalgia of bilateral lower limbs |
| G89.0 | Central pain syndrome |
| G89.29 | Other chronic pain |
| G89.3 | Neoplasm related pain (acute) (chronic) |
| G89.4 | Chronic pain syndrome |
| G90.521 | Complex regional pain syndrome I of right lower limb |
| G90.522 | Complex regional pain syndrome I of left lower limb |
| G90.523 | Complex regional pain syndrome I of lower limb, bilateral |
| M96.1 | Postlaminectomy syndrome, not elsewhere classified |

| Reviews, Revisions, and Approvals | Date | Approval Date |
| --- | --- | --- |
| Policy developed. Specialist reviewed. | 02/19 | 02/19 |
| Added CPT codes: 62320, 62321, 62351, 62361 | 07/19 |  |

### References

1. Portenoy RK, Copenhaver DJ. Cancer pain management: Interventional therapies. In: UpToDate. Abrahm J, Fishman S (Eds), UpToDate, Waltham, MA. Accessed January 31, 2019
2. Hayes Medical Technology Directory. Intrathecal Opioids for Chronic Noncancer Pain. March 27, 2014, updated Feb 9, 2018
3. National Comprehensive Care Network. NCCN Clinical Practice Guidelines in Oncology. Adult Cancer Pain. Version 1.2019-January 25, 2019
4. Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations for Trialing of Intrathecal Drug Delivery Infusion Therapy. Neuromodulation. 2017 Feb;20(2):133-154. doi: 10.1111/ner.12543. Epub 2017 Jan 2
5. Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. Pain Physician. 2013 Apr;16(2 Suppl):S49-283.
6. American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010;112(4):810-833
7. Rosenquist R. Use of opioids in the management of chronic non-cancer pain. In: UpToDate, Aronson MD, Fishman S (Eds), UpToDate, Waltham MA. Accessed February 11, 2019
8. Health Quality Ontario. Ontario Health Technology Assessment Series. Intrathecal Drug Delivery Systems for Noncancer Pain: A Health Technology Assessment. Jan 2016. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761861/pdf/ohtas-16-1.pdf>
9. Intrathecal Drug Delivery Systems. North American Spine Society Coverage Policy Recommendations 2017.
10. Hayek SM, Deer TR, Pope JE, Panchal SJ, Patel VB. Intrathecal therapy for cancer and non-cancer pain. Pain Physician 2011; 14:219-248.
11. Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012 Oct;13(10):1304-13.
12. Pope JE, Deer TR, Bruel BM, Falowski S. Clinical Uses of Intrathecal Therapy and Its

Placement in the Pain Care Algorithm. Pain Pract. 2016 Nov;16(8):1092-1106. doi: 10.1111/papr.12438. Epub 2016 Feb 23.

1. Raffaeli W, Righetti D, Caminiti A, et al. Implantable intrathecal pumps for the treatment of noncancer chronic pain in elderly population: drug dose and clinical efficacy. Neuromodulation. 2008 Jan;11(1):33-9. doi: 10.1111/j.1525-1403.2007.00140.x.
2. Roberts LJ, Finch PM, Goucke CR, Price LM. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain. 2001;5(4):353-61.
3. Lara NA, Jr., Teixeira MJ, Fonoff ET. Long term intrathecal infusion of opiates

for treatment of failed back surgery syndrome. Acta Neurochir Suppl 2011; 108:41-47

1. Galica RJ, Hayek SM, Veizi E, et al. Intrathecal Trialing of Continuous Infusion Combination Therapy With Hydromorphone and Bupivacaine in Failed Back Surgery Patients. Neuromodulation. 2018 Oct;21(7):648-654. doi: 10.1111/ner.12737. Epub 2017 Dec 5.
2. Patel VB, Manchikanti L, Singh V, et al. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician. 2009 Mar-Apr;12(2):345-60.
3. Thimineur MA, Kravitz E, Vodapally MS. Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. Pain. 2004 Jun;109(3):242-9.
4. Duarte RV, Raphael JH, Sparkes E, et al. Long-term intrathecal drug administration for chronic nonmalignant pain. J Neurosurg Anesthesiol. 2012 Jan;24(1):63-70.
5. Hruschak V, Cochran G, Wasan AD. Psychosocial interventions for chronic pain and comorbid prescription opioid use disorders: A narrative review of the literature. J Opioid Manag. 2018 Sep/Oct;14(5):345-358. doi: 10.5055/jom.2018.0467.
6. Majeed MH, Ali AA, Sudak DM. Psychotherapeutic interventions for chronic pain: Evidence, rationale, and advantages. Int J Psychiatry Med. 2019 Mar;54(2):140-149. doi: 10.1177/0091217418791447. Epub 2018 Aug 9.

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members,** to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2018 Centene Corporation. All rights reserved.  All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law.  No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.